Cutting-edge artificial intelligence models are revolutionizing biomedical research, as exemplified by the development of PepMLM, an AI that designs peptide binders without structural data, expanding druggable targets. Separately, researchers pioneered AI-driven chemical LLM named GAMES accelerating molecular encoding in drug design. These innovations demonstrate the power of AI to harness large data and discover novel therapeutics and modalities, addressing historically undruggable proteins and speeding therapeutic development.